Skip to main navigation

+44 (0)20 8154 4600
info@achillestx.com

Home
About Us
Science
Publications
Pipeline
- PIPELINE
- EXPANDED ACCESS
Investors & Media
CAREERS
Contact

Press Releases

Home
About Us
Science
Publications
Pipeline
- PIPELINE
- EXPANDED ACCESS
Investors & Media
CAREERS
Contact

Year

All News
2024
2023
2022
2021
2020
2019
2018
2017
2016

Nov 14 2019

Achilles Therapeutics to Present at the Jefferies 2019 London Healthcare Conference

Read More +

Oct 21 2019

Achilles Therapeutics Appoints Beverley Carr as Chief Business Officer — Brings 20+ years of business development experience — Formerly VP, Business Development for the Immuno-inflammation Therapy Area at GSK

Read More +

Sep 3 2019

ACHILLES THERAPEUTICS RAISES £100 MILLION IN OVERSUBSCRIBED SERIES B FINANCING

Read More +

Feb 13 2019

ACHILLES THERAPEUTICS RECEIVES CTA APPROVAL FOR PHASE I/II STUDY IN METASTIC OR RECURRENT MELANOMA — Second CTA approval in 2019 — the first was for a NSCLC study

Read More +

Jan 21 2019

ACHILLES THERAPEUTICS RECEIVES CTA APPROVAL FOR PHASE I/II STUDY IN NON-SMALL CELL LUNG CANCER — Ground-breaking clinical trial in patients with significant unmet medical need to start this year

Read More +

Dec 10 2018

ACHILLES THERAPEUTICS APPOINTS DR EDWIN MOSES AS CHAIRMAN OF ITS BOARD OF DIRECTORS AND DR IRAJ ALI AS CHIEF EXECUTIVE OFFICER

Read More +

Sep 19 2018

ACHILLES TODAY ANNOUNCES THAT IT HAS APPOINTED SENIOR PHARMACEUTICAL EXECUTIVE MICHAEL F. GIORDANO, M.D., TO ITS BOARD OF DIRECTORS.

Read More +

Apr 26 2017

ACHILLES’ FOUNDERS MAP TRUNCAL AND BRANCHED MUTATIONS AND COPY NUMBER EVENTS TO PREDICT EARLY RELAPSE IN NON-SMALL CELL LUNG CANCER.

Read More +

Jan 3 2017

ACHILLES STARTS 2017 WITH MOVE TO STEVENAGE BIOSCIENCE CATALYST

Read More +

Sep 28 2016

ACHILLES LAUNCHES WITH FUNDS OF £13.2M TO DEVELOP IMMUNOTHERAPIES FOR CANCER

Read More +

Pagination

First page
Previous page
Page 1
Page 2
Page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Current page 9

Print Page

RSS Feeds

Email Alerts

Contact IR

Home
About Us
Science
Publications
Pipeline
Investors & Media
Work with us
Contact

UK Headquarters:
Achilles Therapeutics plc
245 Hammersmith Road
London
W6 8PW, UK

US Headquarters:
Achilles Therapeutics US, Inc.
401 N. Broad Street
Suite M121
Philadelphia, PA 19108

+44 (0)20 8154 4600
info@achillestx.com

© Copyright - Achilles Therapeutics plc.

Achilles Therapeutics plc (13027460) is registered in England and Wales. The registered office is at 245 Hammersmith Road, London, W6 8PW.

Privacy & Cookie Policy

Terms & Conditions